Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8760726 | 0.90 | TSHR (0.61) | DRD4TSHRGAADRD2DRD3 | |
| SCHEMBL15341674 | 0.89 | MAOA (0.62) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL10810933 | 0.88 | DRD4 (0.50) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL11179375 | 0.88 | TDP1 (0.67) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL893830 | 0.88 | TDP1 (0.67) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL7134228 | 0.88 | TSHR (0.58) | MEN1KMT2ATDP1DRD4TSHR | |
| SCHEMBL5232965 | 0.82 | TSHR (0.52) | TSHRGAAADRA1DADRA1AADRA1B | |
| SCHEMBL6342799 | 0.82 | TSHR (0.52) | DRD4TSHRGAAADRA1DADRA1A | |
| SCHEMBL17177749 | 0.82 | DRD4 (0.59) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL7574369 | 0.82 | DRD4 (0.59) | MEN1KMT2ATDP1DRD4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9427604-B2 | Use of benzyloxy-ethylamine derivatives as a preservative, preservation method, and compositions | L'OREAL (FR) | 2016-08-30 | — | — | US | disclosed |
| US-9427604-B2 | Use of benzyloxy-ethylamine derivatives as a preservative, preservation method, and compositions | L'OREAL (FR) | 2016-08-30 | — | — | US | disclosed |
| EP-2509570-B1 | USE OF BENZYLOXY-ETHYLAMINE DERIVATIVES AS A PRESERVATIVE, PRESERVATION METHOD, AND COMPOSITIONS | ORÉAL L (FR) | 2015-10-07 | — | — | EP | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20120269740-A1 | USE OF BENZYLOXY-ETHYLAMINE DERIVATIVES AS A PRESERVATIVE, PRESERVATION METHOD, AND COMPOSITIONS | L'OREAL (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120269740-A1 | USE OF BENZYLOXY-ETHYLAMINE DERIVATIVES AS A PRESERVATIVE, PRESERVATION METHOD, AND COMPOSITIONS | L'OREAL (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-0429149-B1 | Tricyclic pteridinones and a process for their preparation | BERLEX LAB (US) | 2000-01-05 | — | — | EP | disclosed |
| US-5854419-A | Tricyclic pteridinones and a process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-29 | — | — | US | disclosed |
| US-5602252-A | Tricyclic pteridinones and a process for their preparation | BERLEX LABORATORIES, INC. | 1997-02-11 | — | — | US | disclosed |
| EP-0172632-B1 | Benzopyrano[4,3,2-cd]indazole compounds, processes for their production and pharmaceutical compositions comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4604390-A | FUNGICIDES, ANTITUMOR AGENTS | WARNER-LAMBERT COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0172632-A1 | Benzopyrano[4,3,2-cd]indazole compounds, processes for their production and pharmaceutical compositions comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | MEN1 4329/4885KMT2A 3898/4885TDP1 2061/4885 |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | MEN1 3531/4885KMT2A 3635/4885TDP1 1177/4885 |
| US-20120269740-A1 | USE OF BENZYLOXY-ETHYLAMINE DERIVATIVES AS A PRESERVATIVE, PRESERVATION METHOD, AND COMPOSITIONS | H1-0, TET2, TYR | MEN1 815/4885KMT2A 208/4885TDP1 286/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | MEN1 2751/4885KMT2A 4186/4885TDP1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.